Malignant chondroid syringoma: Report of a case with lymph node metastasis 12 years after local excision
- Author(s): Watarai, Akira;
- Amoh, Yasuyuki;
- Aki, Ryoichi;
- Takasu, Hiroshi;
- Katsuoka, Kensei
- et al.
Published Web Locationhttps://doi.org/10.5070/D30568f3qz
Malignant chondroid syringoma: Report of a case with lymph node metastasis 12 years after local excisionKitasato University School Of Medicine, Sagamihara, Kanagawa, Japan
Akira Watarai MD, Yasuyuki Amoh MD, Ryoichi Aki MD, Hiroshi Takasu MD, Kensei Katsuoka
Dermatology Online Journal 17 (9): 5
A 46-year-old man noticed a nodule on his sole. The nodule was removed and the specimen showed a lobular proliferation of tumor cells with glandular differentiation embedded in mucinous stroma. A diagnosis of chondroid syringoma was made. Twelve years later, he noted a swelling in the right inguinal region. The mass was surgically removed. The histopathological findings of the lymph node showed the more atypical tumor cells in the mucoid stroma. Upon reexamination, the primary tumor contained malignant chondroid syringoma (MCS) cells; the tumor cells metastasized to lymph node. MCS is rare with 43 reported cases in the literature. The site of the primary tumor was the lower extremity in 35 percent, the head in 28 percent, and the upper extremity in 23 percent. The percentage of malignant cases with local recurrence, nodal metastasis, and distant metastasis was 49 percent, 42 percent, and 40 percent, respectively. In these cases, the average time period until disease recurrence was 23 months, 50 months, and 66 months for local recurrence, nodal metastasis, and distant metastasis, respectively. Of these, 23 percent of the cases succombed. As MCS may progress very slowly and disease recurrence including metastasis occurs in a relatively high percentage of cases, long-term follow-up of MCS cases is required.
Malignant chondroid syringoma (MCS) is an extremely rare tumor arising from the sweat glands. Although MCS may progress very slowly, there is a high percentage of disease recurrence including metastasis. Here, we report a case of MCS that developed on the sole of a patient. Metastasis to the right inguinal lymph node became apparent 12 years after local excision of the primary nodule.
|Figure 2b||Figure 2c|
A 46-year-old man noticed an asymptomatic, enlarging nodule on the sole of his right foot for 2 years prior to presenting for a medical examination in 1996.. A biopsy had been performed biopsy at another hospital before coming to our hospital, but the tumor remained undiagnosed. On physical examination, a solitary, dome-shaped, skin-colored, and firm nodule, measuring 30 mm x 30 mm, was noted on the sole of his right foot (Figure 1). The nodule was surgically removed along with a 3 mm margin and the defect was replaced with split skin grafting. The surgical specimen showed a lobular proliferation of tumor cells with glandular differentiation associated with a few mitotic cells, embedded in a mucinous stroma (Figures 2a, 2b, and 2c). Immunohistochemistry showed that the majority of tumor cells were positive for PAS diastase, toluidine blue, cytokeratins (CAM5.2, CK7), S-100 protein, and GCDFP-15. From the above findings, although there appeared to be some atypical tumor cells, a diagnosis of chondroid syringoma was made. Surgical margins were negative. Ultrasound of the regional lymph nodes and radiography of the chest and abdomen showed no evidence of metastasis.
|Figure 3a||Figure 3b|
|Figure 3. Pathological examination of the resected inguinal lymph node. (3a: H&E, x12.5) showed the more atypical tumor cells in the mucoid stroma compared to the primary nodule of the sole. (3b: H&E, x100)|
In 2008, 12 years after the initial presentation, the patient noticed a swelling in the right inguinal region. Ultrasound of the area revealed a mass measuring 30 mm x 30 mm in the right inguinal region. The mass was surgically removed. The histopathological findings of the resected lymph node showed the more atypical tumor cells in the mucoid stroma, compared to the primary nodule of the sole (Figures 3a and 3b). From the behavior of the tumor, we reconsidered that the primary tumor contained the malignant chondroid syringoma (MCS) cells, and the tumor cells had metastasized to lymph node. MRI revealed no recurrence on the sole. CT scan of the head, thorax, abdomen, and pelvis were negative. Gallium scintigraphy revealed no abnormalities. The patient received radiation treatment in the right inguinal region and chemotherapy with tegafur, gimeracil, and oteracil potassium for one year. On follow-up 18 months after excision of the right inguinal lymph node, the patient showed no signs of local recurrence or distant metastasis.
Chondroid syringoma was first described by Hirsch & Helwig in 1961 . Chondroid syringoma is a rare, benign tumor of the skin that arises from the sweat glands. Rarely, a chondroid syringoma of many years duration may undergo sudden malignant change with subsequent widespread metastasis. The aggressiveness of MCS can vary. For example, most cases had local recurrence, but some cases showed regional lymph node or osseous metastasis. When this tumor metastasizes, it displays features of an adenocarcinoma on histopathology and often loses the tendency to form chondroid stroma. Only 43 MCS cases have been previously reported (Table 1) [1-37]. In the 43 patients, the site of the primary tumor was the lower extremity in 15 (35%), the head in 12 (28%), the upper extremity in 10 (23%), and the trunk in 6 (14%). MCS tends to follow an unpredictable clinical course. Approximately 49 percent of MCS cases have local recurrence. Nodal and distant metastasis was observed in approximately 42 percent and 40 percent of cases, respectively. These percentages suggest that disease recurrence is relatively high with MCS. Surgery was performed in all 43 MCS cases, of which 9 were given radiotherapy, 2 were treated with chemotherapy, and 5 were treated with a combination of radiotherapy and chemotherapy. In the 43 patients, 10 (23%) were dead, 20 (47%) were alive, and 13 (30%) were unknown. In those who later succumbed, the period of survival was from 6 months to 7 years (mean: 4.9 years). Barnett et al. recommended adjuvant radiotherapy for all chondroid syringomas showing signs of aggressiveness or cytologic atypia, regardless of whether it is an initial presentation or a recurrence, because of the seemingly unpredictable nature of this disease and the difficulty faced in removing it completely by excision .
Radiotherapy and chemotherapy have no proven value in treatment and adequate surgical excision with wide disease-free margins is the best way to achieve disease control. Chemotherapy and radiotherapy is administered to patients with advanced disease.
In the 43 cases of MCS, the average time period until disease recurrence was 23 months, 50 months, and 66 months for local recurrence, nodal metastisis, and distant metastasis, respectively. In our case, metastasis was discovered 12 years after removal of the primary tumor. The differential diagnosis of this tumor is an apocrine carcinoma and other kinds of myxoid tumors, such as extraskeletal myxoid chondrosarcoma. In our case, the tumor occurred from a sole that does not contain apocrine gland. The tumor had some chondroid stroma and it was present in the dermis and did not demonstrate any connection between the underlying muscle and bone; positive staining for cytokeratins, S-100 protein and GCDFP-15 was observed. These histopathological features, combined with the aggressive behavior of the tumor, led to the diagnosis of MCS. Although there was no evidence of other nodal or distant metastasis, we considered the possibility that neoplastic cells persisted. Therefore, the patient was given radiotherapy in the right inguinal region and chemotherapy with tegafur, gimeracil, and oteracil potassium for one year. In two reported cases, lymph node and lung metastasis was noted 11 years and 17 years after the excision of MCS, respectively [5, 6]. As MCS may progress very slowly, and disease recurrence including metastasis occurs in a relatively high percentage of cases, long-term follow-up of MCS cases is required.
References1. Hirsch P, Helwig EB. Chondroid syringoma. Mixed tumor of skin, salivary gland type. Arch Dermatol. 1961 Nov;84:835-47. [PubMed]
2. Barnett MD, Wallack MK, Zuretti A, Mesia L, Emery RS, Berson AM. Recurrent malignant chondroid syringoma of the foot: a case report and review of the literature. Am J Clin Oncol. 2000 Jun;23(3):227-32. [PubMed]
3. Hilton JM, Blackwell JB. Metastasising chondroid syringoma. J Pathol. 1973 Feb;109(2):167-70. [PubMed]
4. Kiely JL, Dunne B, McCabe M, McNicholas WT. Malignant chondroid syringoma presenting as multiple pulmonary nodules. Thorax. 1997 Apr;52(4):395-6. [PubMed]
5. Devine P, Sarno RC, Ucci AA. Malignant cutaneous mixed tumor. Arch Dermatol. 1984 May;120(5):576-7. [PubMed]
6. Trown K, Heenan PJ. Malignant mixed tumor of the skin (malignant chondroid syringoma). Pathology. 1994 Jul;26(3):237-43. [PubMed]
7. Metzler G, Schaumburg-Lever G, Hornstein O, Rassner G. Malignant chondroid syringoma: immunohistopathology. Am J Dermatopathol. 1996 Feb;18(1):83-9. [PubMed]
8. Gupta S, Kumar A, Padmanabhan A, Khanna S. Malignant chondroid syringoma: a clinicopathological study and a collective review. J Surg Oncol. 1982 Jul;20(3):139-44. [PubMed]
9. Matz LR, McCully DJ, Stokes BA. Metastasizing chondroid syringoma: case report. Pathology. 1969 Jan;1(1):77-81. [PubMed]
10. Solomonov A, Rosenblatt E, Ben-Izhak O, Goralnik L, Yigla M. High-dose-rate endobronchial brachytherapy in endobronchial metastatic malignant chondroid syringoma. Respiration. 2001;68(4):406-10. [PubMed]
11. Medina Henriquez JA, Navarro Garcia R, Nagel D, Foucher G. Malignant chondroid syringoma of the hand: a case report. Scand J Plast Reconstr Surg Hand Surg. 2001 Dec;35(4):437-9. [PubMed]
12. Takahashi H, Ishiko A, Kobayashi M, Tanikawa A, Takasu H, Md MT. Malignant chondroid syringoma with bone invasion: a case report and review of the literature. Am J Dermatopathol. 2004 Oct;26(5):403-6. [PubMed]
13. Shashikala P, Chandrashekhar HR, Sharma S, Suresh KK. Malignant chondroid syringoma. Indian J Dermatol Venereol Leprol. 2004 May-Jun;70(3):175-6. [PubMed]
14. Mathiasen RA, Rasgon BM, Rumore G. Malignant chondroid syringoma of the face: a first reported case. Otolaryngol Head Neck Surg. 2005 Aug;133(2):305-7. [PubMed]
15. Agrawal V, Gupta RL, Kumar S, Mishra K, Agarwal S. Malignant chondroid syringoma. J Dermatol. 1998 Aug;25(8):547-9. [PubMed]
16. Bates AW, Baithun SI. Atypical mixed tumor of the skin: histologic, immunohistochemical, and ultrastructural features in three cases and a review of the criteria for malignancy. Am J Dermatopathol. 1998 Feb;20(1):35-40. [PubMed]
17. Botha JB, Kahn LB. Aggressive chondroid syringoma. Report of a case in an unusual location and with local recurrence. Arch Dermatol. 1978 Jun;114(6):954-5. [PubMed]
18. Clark P. Malignant chondroid syringoma. Conn Med. 1987 Sep;51(9):569-72. [PubMed]
19. Dissanayake RV, Salm R. Sweat-gland carcinomas: prognosis related to histological type. Histopathology. 1980 Jul;4(4):445-66. [PubMed]
20. Harrist TJ, Aretz TH, Mihm MC Jr, Evans GW, Rodriquez FL. Cutaneous malignant mixed tumor. Arch Dermatol. 1981 Nov;117(11):719-24. [PubMed]
21. Hermann G, Moss D, Norton KI, Guttenberg ME. Case report 450: Skeletal metastases secondary to malignant chondroid syringoma. Skeletal Radiol. 1987;16(8):657-9. [PubMed]
22. Hong JJ, Elmore JF, Drachenberg CI, Jacobs MC, Salazar OM. Role of radiation therapy in the management of malignant chondroid syringoma. Dermatol Surg. 1995 Sep;21(9):781-5. [PubMed]
23. Ishimura E, Iwamoto H, Kobashi Y, Yamabe H, Ichijima K. Malignant chondroid syringoma. Report of a case with widespread metastasis and review of pertinent literature. Cancer. 1983 Nov 15;52(10):1966-73. [PubMed]
24. Lucas GL, Nordby EJ. Sweat gland carcinoma of the hand. Hand. 1974 Feb;6(1):98-102. [PubMed]
25. Nather A, Sutherland IH. Malignant transformation of a benign cutaneous mixed tumour. J Hand Surg Br. 1986 Feb;11(1):139-43. [PubMed]
26. Pinto de Moraes H, Herrera GA, Mendonca AM, Estrela RR. Metastatic malignant mixed tumor of the skin. Ultrastructural and immunocytochemical characterization, histogenetic considerations and comparison with benign mixed tumors of skin and salivary glands. Appl Pathol. 1986;4(3):199-208. [PubMed]
27. Redono C, Rocamora A, Villoria F, Garcia M. Malignant mixed tumor of the skin: malignant chondroid syringoma. Cancer. 1982 Apr 15;49(8):1690-6. [PubMed]
28. Rosborough D. Malignant Mixed Tumours Of Skin. Br J Surg. 1963 Jul;50:697-9. [PubMed]
29. Sánchez Yus E, Aguilar A, Urbina F, Cristóbal MC, Vázquez F, Requena L. Malignant cutaneous mixed tumor. A new case with unusual clinical features. Am J Dermatopathol. 1988 Aug;10(4):330-4. [PubMed]
30. Scott A, Metcalf JS. Cutaneous malignant mixed tumor. Report of a case and review of the literature. Am J Dermatopathol. 1988 Aug;10(4):335-42. [PubMed]
31. Seenu V, Goel AK, Shukla NK, Prakash MB, Mohan R. Malignant chondroid syringoma of scalp with cervical lymph node metastases. J Assoc Physicians India. 1996 Aug;44(8):565-6. [PubMed]
32. Sharvill DE. Mixed salivary-type tumour of the skin with malignant recurrence. Br J Dermatol. 1962 Mar;74:103-4. [PubMed]
33. Shvili D, Rothem A. Fulminant metastasizing chondroid syringoma of the skin. Am J Dermatopathol. 1986 Aug;8(4):321-5. [PubMed]
34. Steinmetz JC, Russo BA, Ginsburg RE. Malignant chondroid syringoma with widespread metastasis. J Am Acad Dermatol. 1990 May;22(5 Pt 1):845-7. [PubMed]
35. Sun TB, Chien HF, Huang SF, Shih TT, Chen MT. Malignant chondroid syringoma. J Formos Med Assoc. 1996 Jul;95(7):575-8. [PubMed]
36. Watson JA, Walker MM, Smith NP, Hunt DM. Malignant chondroid syringoma--a rare cause of secondary bone tumour. Clin Exp Dermatol. 1991 Jul;16(4):306-7. [PubMed]
37. Webb JN, Stott WG. J Pathol. Malignant chondroid syringoma of the thigh. Report of a case with electron microscopy of the tumour. 1975 May;116(1):43-6.
© 2011 Dermatology Online Journal